

REMARKS

Further to the claim amendments set forth in Applicants' March 18, 2005 reply to the Office Action mailed on November 18, 2004, claims 1, 50, and 51 have been amended to clarify to claim language.

The amendment to claim 1 clarifies that the isolated glycoprotein includes a naturally-occurring human amino acid primary structure of CD55 and the amendment to claim 50 clarifies that the glycosylated human CD55 protein expressed by adenocarcinoma cell line 23132 is naturally-occurring. Support for these amendments may be found, for example, at page 4, lines 7-11, page 5, lines 18-23, and page 6, lines 20-22, of the English language specification.

As amended, claim 51 requires an antibody that specifically binds the tumor-specific N-linked glycostructure of the section to induce apoptosis of a cell expressing a glycosylated human CD55 protein containing the tumor-specific N-linked glycostructure. This amendment finds support, for example, at page 4, lines 15-21, of the English language specification. No new matter has been added by the present amendments.

06-06-05

18:00

From-CLARK & ELBING LLP

+6174287023

T-250 P.008/008 F-272


CONCLUSION


Applicants submit that the application is now in condition for allowance and this action is hereby respectfully requested.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: June 6, 2005


Kristina Bicker-Brady, Ph.D.
Reg. No. 39,109


Jan R. Titter, Ph.D.
Reg. No. 52,290

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045